|Table of Contents|

The value of mSEPT9 detection in the diagnosis and recurrence monitoring of colorectal cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 15
Page:
2783-2788
Research Field:
Publishing date:

Info

Title:
The value of mSEPT9 detection in the diagnosis and recurrence monitoring of colorectal cancer
Author(s):
CHEN Jiaojiao; LI Rong; ZHANG Ke; HU Fengdi; XIE Lin
Department of Gastrointestinal Oncology，the Third Affiliated Hospital of Kunming Medical University，Tumor Hospital of Yunnan Province,Yunnan Kunming 650118,China.
Keywords:
colorectal cancer; mSEPT9; diagnosis; recurrence
PACS:
R735.3
DOI:
10.3969/j.issn.1672-4992.2024.15.014
Abstract:
Objective:To investigate the value of Septin9 gene methylation(mSEPT9) in the diagnosis and recurrence monitoring of colorectal cancer(CRC).Methods:From January 2018 to December 2021,130 patients with CRC who were diagnosed and underwent radical surgery in the hospital were retrospectively analyzed,and 132 patients without CRC at the same time were selected as the control group.There were 72 cases in adenoma group and 60 cases in healthy control group.To explore the role of plasma mSEPT9 detection in the diagnosis of CRC,and to analyze the significance of mSEPT9 in the monitoring of postoperative recurrence in CRC patients.Results:The positive rates of plasma mSEPT9 and serum CEA in healthy control group and adenoma group were lower than those in colorectal cancer group,and the differences were statistically significant(P＜0.05).The risk factors of CRC were listed separately and quantified in the form of scores,and a nomogram for predicting the probability of CRC was generated.Multivariate Logistic regression analysis showed that TNM stage(Ⅲ,Ⅳ) and preoperative mSEPT9 positive were independent risk factors for postoperative recurrence of CRC patients(P＜0.05).Conclusion:Plasma mSEPT9 can be used as a molecular marker for the diagnosis of CRC and monitoring postoperative recurrence.

References:

［1］BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］BACOLOD MD,MIRZA AH,HUANG J,et al.Application of multiplex bisulfite PCR-ligase detection reaction-real time quantitative PCR assay in interrogating bioinformatically identified,blood-based methylation markers for colorectal cancer［J］.J Mol Diagn,2020,22(7):885-900.
［3］WU C,LI M,MENG H,et al.Analysis of status and countermeasures of cancer incidence and mortality in China［J］.Sci China Life Sci,2019,62(5):640-647.
［4］SUN J,FEI F,ZHANG M,et al.The role of (m)SEPT9 in screening,diagnosis,and recurrence monitoring of colorectal cancer［J］.BMC Cancer,2019,19(1):450.
［5］LOOMANS-KROPP HA,SONG Y,GALA M,et al.Methylated Septin9(mSEPT9):A promising blood-based biomarker for the detection and screening of early-onset colorectal cancer［J］.Cancer Res Commun,2022,2(2):90-98.
［6］MA J,ZHOU Y,LI W,et al.Association between plasma HMGB-1 and silicosis:A case-control study［J］.Int J Mol Sci,2018,19(12):4043.
［7］XIE L,JIANG X,LI Q,et al.Diagnostic value of methylated Septin9 for colorectal cancer detection［J］.Front Oncol,2018,8:247.
［8］LEE JD,MCDONALD TS,FUNG J,et al.Absence of receptor for advanced glycation end product(RAGE) reduces inflammation and extends survival in the hSOD1(G93A) mouse model of amyotrophic lateral sclerosis［J］.Mol Neurobiol,2020,57(10):4143-4155.
［9］SANTOS G,BARATEIRO A,BRITES D,et al.S100B impairs oligodendrogenesis and myelin repair following demyelination through RAGE engagement［J］.Front Cell Neurosci,2020,14:279.
［10］MIN L,CHEN J,YU M,et al.Using circulating tumor DNA as a novel biomarker to screen and diagnose colorectal cancer:A Meta-analysis［J］.J Clin Med,2023,12(2):408.
［11］SUN G,MENG J,DUAN H,et al.Diagnostic assessment of Septin9 DNA methylation for colorectal cancer using blood detection:A Meta-analysis［J］.Pathol Oncol Res,2019,25(4):1525-1534.
［12］HU J,HU B,GUI YC,et al.Diagnostic value and clinical significance of methylated SEPT9 for colorectal cancer:A Meta-analysis［J］.Med Sci Monit,2019,25:5813-5822.
［13］HARIHARAN R,JENKINS M.Utility of the methylated SEPT9 test for the early detection of colorectal cancer:A systematic review and meta-analysis of diagnostic test accuracy［J］.BMJ Open Gastroenterol,2020,7(1):e000355.
［14］JIN P,KANG Q,WANG X,et al.Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm［J］.J Gastroenterol Hepatol,2015,30(5):830-833.
［15］WU D,ZHOU G,JIN P,et al.Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening［J］.J Mol Diagn,2016,18(4):535-545.
［16］LEE HS,HWANG SM,KIM TS,et al.Circulating methylated septin 9 nucleic Acid in the plasma of patients with gastrointestinal cancer in the stomach and colon［J］.Transl Oncol,2013,6(3):290-296.
［17］LU DC,ZHANG QF,LI L,et al.Methylated Septin9 has moderate diagnostic value in colorectal cancer detection in Chinese population:A multicenter study［J］.BMC Gastroenterol,2022,22(1):232.
［18］LU P,ZHU X,SONG Y,et al.Methylated Septin 9 as a promising biomarker in the diagnosis and recurrence monitoring of colorectal cancer［J］.Dis Markers,2022,2022:7087885.
［19］CHURCH TR,WANDELL M,LOFTON-DAY C,et al.Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer［J］.Gut,2014,63(2):317-325.
［20］LIU W,HU P,LIU J,et al.mSEPT9 can monitor the response and predict the prognosis of stage Ⅳ colorectal cancer patients with liver metastasis undergoing potentially curative surgery［J］.J Surg Res,2021,267:485-494.
［21］WANG YJ,ZHANG R,LI Y.Advances in abnormal DNA methylation and related regulatory genes in AML［J］.Modern Oncology，2021，29(19):3491-3494.
［22］CHEN X,LI LS,CHEN YL.Advance of DNA methylation in tumor diagnosis and anti tumor therapy［J］.Modern Oncology，2017，25(9):1476-1480.
［23］YE JG,TIAN LH,HUANG YG.Advances in research of DNA methylation in lung cancer［J］.Modern Oncology，2016，24(22):3659-3663.
［24］SUN J,ZHENG MY,LI YW,et al.Structure and function of Septin 9 and its role in human malignant tumors［J］.World J Gastrointest Oncol,2020,12(6):619-631.
［25］ROMEIH S,KAOUD A,SHAABAN M,et al.Coronary artery anomalies in tetralogy of Fallot patients evaluated by multi slice computed tomography,myocardial bridge is not a rare finding［J］.Medicine(Baltimore),2021,100(7):e24325.
［26］GAO JJ,WANG YW,LI Y,et al.Performance of circulating methylated Septin9 gene DNA in diagnosis and recurrence monitoring of colorectal cancer in Western China［J］.Clin Chim Acta,2022,537:118-126.
［27］YUAN Z,WANG S,NI K,et al.Circulating methylated SEPT9 DNA analyses to predict recurrence risk and adjuvant chemotherapy benefit in stage Ⅱ to Ⅲ colorectal cancer［J］.Med Sci Monit,2022,28:e937757.
［28］HUANG M,HE J,LAI W,et al.Methylated septin 9 gene is an important prognostic marker in stage Ⅱ and stage Ⅲ colorectal cancer for evaluating local recurrence or distant metastasis after surgery［J］.BMC Gastroenterol,2022,22(1):87.
［29］JIANG H,YU Q,CHEN X,et al.Role of blood mSEPT9 in evaluating tumor burden and disease monitoring in colorectal cancer patients［J］.J Clin Lab Anal,2021,35(11):e24030.
［30］YANG X,XU ZJ,CHEN X,et al.Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients［J］.World J Gastroenterol,2019,25(17):2099-2109.
［31］SUN J,XU J,SUN C,et al.Screening and prognostic value of methylated Septin9 and its association with clinicopathological and molecular characteristics in colorectal cancer［J］.Front Mol Biosci,2021,8:568818.

Memo

Memo:
云南省科技厅基础研究计划（编号：202101AY070001-177）
Last Update: 2024-06-28